Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724646 | 1.00 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2CPT2CPT1A | |
| SCHEMBL21724650 | 1.00 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2CPT2CPT1A | |
| SCHEMBL21724268 | 1.00 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2CPT2CPT1A | |
| SCHEMBL21732823 | 0.89 | EPHX1 (0.51) | EPHX1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL21732778 | 0.89 | EPHX1 (0.51) | EPHX1SMN1; SMN2CPT2CPT1ACPT1B | |
| SCHEMBL4585800 | 0.85 | EPHX1 (0.56) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL4585168 | 0.85 | EPHX1 (0.56) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL4585179 | 0.85 | EPHX1 (0.56) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL24096091 | 0.84 | EPHX1 (0.54) | EPHX1SMN1; SMN2EPHX2CPT2CPT1A | |
| SCHEMBL4586041 | 0.82 | EPHX1 (0.63) | EPHX1SMN1; SMN2CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | EPHX1 1102/4885SMN1; SMN2 1714/4885EPHX2 302/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | EPHX1 1102/4885SMN1; SMN2 1714/4885EPHX2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.